Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 18, 2018

View Archived Issues

Tau PET ligand[18F]PM-PBB3 shows promising characteristics in patients

Curis announces initiation of phase I study of CA-4948 in patients with lymphoma

FDA accepts two IND applications for OP-687

Endari now available in U.S. for sickle cell disease in adult and pediatric patients

Onconova continues INSPIRE trial of rigosertib based on DMC recommendation

Darbepoetin alfa biosimilar JR-131 demonstrates equivalence in phase III study

Isofol holds end of phase II meeting for Modufolin in advanced colorectal cancer

Aeterna Zentaris, Strongbridge Biopharma enter Macrilen license agreement

Osel opens study of Lactin-V to improve IVF success rate in women with abnormal vaginal microbiota

Lyric Pharmaceuticals' ulimorelin awarded FDA fast track designation

Arcturus and Takeda extend partnership

PPAOS and agPPA patients show different pattern of [18F]AV-1451 uptake in the brain

JNJ-63623872 reduces influenza viral load and clinical symptoms in phase IIa trial

Spark's SPK-8011 given FDA orphan drug status for hemophilia A

FDA gives Adgero Biopharmaceuticals' rostaporfin orphan status in BCCNS

Novel PET tracer [18F]GE-180 inferior to [11C]-PBR-28 for TSPO quantification in brain

Biohaven begins clinical development of BHV-5000

Universidad de Alcala presents new antioxidant compounds

Hangzhou Huadong Medicine Group Pharmaceutical Research Institute divulges BTK inhibitors

Roche identifies novel gamma-secretase inhibitors

Vasade Biosciences discloses novel adenylate cyclase inhibitors

Idenix and Merck & Co. patent NS5B inhibitors for HCV infection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.